EMEA-003043-PIP01-21 - paediatric investigation plan

alprazolam

Key facts

• Active Substance:
  alprazolam
• Therapeutic area:
  Neurology
• Decision number:
  P/0220/2022
• PIP number:
  EMEA-003043-PIP01-21
• Pharmaceutical form(s):
  Inhalation powder
• Condition(s) / indication(s):
  Treatment of epileptic seizures
• Route(s) of administration:
  Inhalation use
• Contact for public enquiries:

  UCB Pharma SA.

  E-mail: [e-mail]; Tel.: + 353 14632371

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  10/06/2022

Decision

P/0220/2022 : EMA decision of 10 June 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for alprazolam (EMEA-003043-PIP01-21)

AdoptedReference Number: EMA/563180/2022